28 July 2022 - - US-based specialty pharmacy services provider Soleo Health has been selected as a limited distribution partner for cardiovascular drug Leqvio, manufactured by Swiss-American pharmaceutical company Novartis (NYSE: NVS), the company said.

Leqvio (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Leqvio is a subcutaneous injection that Soleo Health will administer to patients in their homes or at one of the company's Ambulatory Infusion Centers nationwide.

Concurrent with the administration of Leqvio, Soleo Health will leverage its proprietary clinical outcomes program, SoleMetrics, to collect and produce valuable real-world data over time for those patients prescribed Leqvio.

SoleMetrics will gather intelligent outcomes from patients throughout their journeys while on Leqvio to deliver clinical and economic value to key stakeholders.

Soleo Health is a national provider of complex specialty pharmacy services administered in the home or at alternate sites of care.

Soleo Health's interdisciplinary clinical team comprises pharmacists, registered nurses, reimbursement specialists and patient care ambassadors.

The company optimizes patient access solutions and delivers comprehensive services, leading to quantifiable clinical and economic value, resulting in positive patient experiences.

Soleo Health operates 21 locations throughout the US with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission.